Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs carboplatin + pemetrexed as first-line chemotherapy in elderly advanced NSCLC
2008-002126-12Phase 2Recruiting
- Sponsor
- Humanitas Research Hospital
- Start
- Jul 2008
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) and bronchial carcinoma comparing Gemcitabine monotherapy with Carboplatin + pemetrexed (2 arms). Primary endpoint: Progression-free survival. Started Jul 2008; status: recruiting.
02
Drugs
gemcitabinecarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)bronchial carcinoma
Beyond the preview
Go deeper on 2008-002126-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-002126-12.